Payment overview · 2025
General Payments
$76.30
4 reported records · 3 companies
Healthcare provider profile · identity verified
Douglas Starr, MD
Allopathic & Osteopathic Physicians|Family Medicine · DIAMOND BAR, CA · NPI 1154322998
Verified facts
What the public records show
CMS Open Payments records show Douglas Starr, MD received $76.30 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 51.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.15 | 51.3% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $22.85 | 29.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.30 | 18.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $76.30 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39.15 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 99 |
| Metformin Hcl | Metformin Hcl | 299 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 286 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 78 |
| Lisinopril | Lisinopril | 270 | 75 |
| Losartan Potassium | Losartan Potassium | 255 | 76 |
| Montelukast Sodium | Montelukast Sodium | 249 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 234 | 68 |
| Simvastatin | Simvastatin | 224 | 62 |
| Famotidine | Famotidine | 209 | 73 |
| Alprazolam | Alprazolam | 177 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 54 |
| Eliquis | Apixaban | 150 | 29 |
| Omeprazole | Omeprazole | 132 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 116 | 36 |
| Furosemide | Furosemide | 115 | 34 |
| Lorazepam | Lorazepam | 102 | 18 |
| Trazodone Hcl | Trazodone Hcl | 100 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 25 |
| Potassium Chloride | Potassium Chloride | 79 | 25 |
| Jardiance | Empagliflozin | 78 | 18 |
| Atenolol | Atenolol | 77 | 24 |
| Allopurinol | Allopurinol | 73 | 22 |
| Benazepril Hcl | Benazepril Hcl | 69 | 19 |
| Clonazepam | Clonazepam | 68 | 14 |
| Celecoxib | Celecoxib | 63 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 29 |
| Gabapentin | Gabapentin | 60 | 22 |
| Carvedilol | Carvedilol | 56 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 15 |
| Azelastine Hcl | Azelastine Hcl | 54 | 23 |
| Tramadol Hcl | Tramadol Hcl | 50 | 12 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 15 |
| Clonidine Hcl | Clonidine Hcl | 47 | 12 |
| Januvia | Sitagliptin Phosphate | 47 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Prednisone | Prednisone | 43 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 13 |
| Farxiga | Dapagliflozin Propanediol | 42 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 40 | 15 |
| Ozempic | Semaglutide | 39 | 13 |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 15 |
| Ibuprofen | Ibuprofen | 37 | 16 |
| Synthroid | Levothyroxine Sodium | 37 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 29 |
| Estradiol | Estradiol | 34 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 34 | 13 |
| Ezetimibe | Ezetimibe | 33 | 12 |
| Glipizide Er | Glipizide | 33 | 11 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Nystatin | Nystatin | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 15 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 24 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | 19 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 16 |
| Ketoconazole | Ketoconazole | 23 | 12 |
| Mupirocin | Mupirocin | 23 | 19 |
| Ramipril | Ramipril | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 16 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Livalo | Pitavastatin Calcium | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 14 |
| Diazepam | Diazepam | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Probenecid | Probenecid | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Baclofen | Baclofen | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Metolazone | Metolazone | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $76.30 · 4 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Flector, Licart, Tirosint, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error